View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
November 15, 2021updated 11 Jul 2022 2:19pm

NewAmsterdam Pharma reports positive data in Phase II dyslipidemia trial 

In the trial, treatment with 5mg and 10mg obicetrapib respectively led to a 42% and 51% decline in LDL-c.

NewAmsterdam Pharma has reported positive data from the Phase II ROSE clinical trial of its experimental drug, obicetrapib, to treat dyslipidemia.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

A selective inhibitor of cholesteryl ester transfer protein, obicetrapib is being developed to reduce low-density lipoprotein cholesterol (LDL-c) and avert crucial adverse cardiovascular events.

The double-blind, placebo-controlled, randomised trial analysed the safety, efficacy and tolerability of obicetrapib in 120 subjects.

These participants were categorised to receive either 5mg or 10mg dose of obicetrapib or placebo for eight weeks.

In the trial, obicetrapib was analysed as a single agent and along with ezetimibe, as an adjunct to high-intensity statin therapy.

Findings showed that treatment with 5mg and 10mg obicetrapib offered a 42% and 51% decline in LDL-c, respectively, versus baseline compared with a 7% decline in the placebo arm.

Nearly 47.5% of the subjects in the placebo arm reported adverse events (AEs) as against 32.5% and 20% in the 5mg and 10mg obicetrapib arms, respectively.

Furthermore, two serious AEs were noted in the placebo group while no serious AEs were observed in the two tretament arms.

Obicetrapib was found to be safe and well-tolerated in trial subjects receiving the treatment.

Subjects treated with 5mg or 10mg doses of the drug reported a 45% and 48% rise in apolipoprotein A-I HDL levels, respectively.

In July, the company had reported that the trial met its primary goal at both the tested doses of the drug.

NewAmsterdam Pharma chief scientific officer John Kastelein said: “These clinical data are tremendously exciting in that they confirm the genetic validation of CETP inhibition as an LDL-lowering mechanism and show the effect of obicetrapib is just as robust in patients on high-intensity statins as it is in patients who are statin-intolerant, which has been a core pillar of our company strategy for developing obicetrapib in cardiovascular diseases and other major diseases of high unmet need.”

The company plans to commence Phase III trials of the drug in the fourth quarter of this year.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena